TY - JOUR
T1 - Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice
AU - Hagino, Yoko
AU - Kasai, Shinya
AU - Fujita, Masayo
AU - Setogawa, Susumu
AU - Yamaura, Hiroshi
AU - Yanagihara, Dai
AU - Hashimoto, Makoto
AU - Kobayashi, Kazuto
AU - Meltzer, Herbert Y.
AU - Ikeda, Kazutaka
N1 - Funding Information:
We acknowledge Drs Minoru Saitoe and Tomoyuki Furuyashiki for critically reading the manuscript, Mr Michael Arends for assistance with editing the manuscript, and Ms Satomi Soma, Ms Junko Wakamatsu, Ms Yurie Nakamoto, and Ms Etsuko Kamegaya for assistance with breeding the DD mice. This work was supported by grants from the Ministry of Health, Labour and Welfare of Japan (H22-Iyaku-015 and H25-Iyaku-020), JSPS KAKENHI Grants 24659549, 24659490, and 24650205, MEXT KAKEN-HI Grant 25116532, the Smoking Research Foundation, the Naito Foundation, and the Astellas Foundation for Research on Metabolic Disorders. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2015 American College of Neuropsychopharmacology. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Dopaminergic systems have been known to be involved in the regulation of locomotor activity and development of psychosis. However, the observations that some Parkinson's disease patients can move effectively under appropriate conditions despite low dopamine levels (eg, kinesia paradoxia) and that several psychotic symptoms are typical antipsychotic resistant and atypical antipsychotic sensitive indicate that other systems beyond the dopaminergic system may also affect locomotor activity and psychosis. The present study showed that dopamine-deficient (DD) mice, which had received daily L-DOPA injections, could move effectively and even be hyperactive 72 h after the last L-DOPA injection when dopamine was almost completely depleted. Such hyperactivity was ameliorated by clozapine but not haloperidol or ziprasidone. Among multiple actions of clozapine, muscarinic acetylcholine (ACh) activation markedly reduced locomotor activity in DD mice. Furthermore, the expression of choline acetyltransferase, an ACh synthase, was reduced and extracellular ACh levels were significantly reduced in DD mice. These results suggest that the cholinergic system, in addition to the dopaminergic system, may be involved in motor control, including hyperactivity and psychosis. The present findings provide additional evidence that the cholinergic system may be targeted for the treatment of Parkinson's disease and psychosis.
AB - Dopaminergic systems have been known to be involved in the regulation of locomotor activity and development of psychosis. However, the observations that some Parkinson's disease patients can move effectively under appropriate conditions despite low dopamine levels (eg, kinesia paradoxia) and that several psychotic symptoms are typical antipsychotic resistant and atypical antipsychotic sensitive indicate that other systems beyond the dopaminergic system may also affect locomotor activity and psychosis. The present study showed that dopamine-deficient (DD) mice, which had received daily L-DOPA injections, could move effectively and even be hyperactive 72 h after the last L-DOPA injection when dopamine was almost completely depleted. Such hyperactivity was ameliorated by clozapine but not haloperidol or ziprasidone. Among multiple actions of clozapine, muscarinic acetylcholine (ACh) activation markedly reduced locomotor activity in DD mice. Furthermore, the expression of choline acetyltransferase, an ACh synthase, was reduced and extracellular ACh levels were significantly reduced in DD mice. These results suggest that the cholinergic system, in addition to the dopaminergic system, may be involved in motor control, including hyperactivity and psychosis. The present findings provide additional evidence that the cholinergic system may be targeted for the treatment of Parkinson's disease and psychosis.
UR - http://www.scopus.com/inward/record.url?scp=84925462870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925462870&partnerID=8YFLogxK
U2 - 10.1038/npp.2014.295
DO - 10.1038/npp.2014.295
M3 - Article
C2 - 25367503
AN - SCOPUS:84925462870
SN - 0893-133X
VL - 40
SP - 1141
EP - 1150
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
ER -